MEDIHALER ERGOTAMINE (ergotamine tartrate) by Teva is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. Approved for migraine. First approved in 1960.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
MEDIHALER ERGOTAMINE is an inhalation aerosol containing ergotamine tartrate, an alpha-adrenergic blocking agent with direct vasoconstrictive effects on cranial blood vessels. It is indicated for acute migraine headache relief and works through peripheral vasoconstriction combined with serotonin antagonism and central vasomotor depression. The addition of caffeine enhances vasoconstrictive efficacy without requiring higher ergotamine doses.
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating a contracting commercial organization focused on market defense rather than expansion.
CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…
Worked on MEDIHALER ERGOTAMINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on MEDIHALER ERGOTAMINE offers limited career growth opportunities given its LOE approaching status and declining market position relative to superior triptan alternatives. Roles focus on defending existing market share and managing transition to post-LOE generics rather than innovation or expansion.